AbCellera Biologics Inc. (ABCL) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 9 Buy, 2 Hold.
The consensus price target is $20.17 (low: $5.00, high: $34.00), representing an upside of 436.4% from the current price $3.76.
Analysts estimate Earnings Per Share (EPS) of $-0.59 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.55 vs est $-0.59 (beat +6.3%). 2025: actual $-0.49 vs est $-0.58 (beat +15.5%). Analyst accuracy: 87%.
ABCL Stock — 12-Month Price Forecast
$20.17
▲ +436.44% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for AbCellera Biologics Inc., the average price target is $20.17, with a high forecast of $34.00, and a low forecast of $5.00.
The average price target represents a +436.44% change from the last price of $3.76.
Highest Price Target
$34.00
Average Price Target
$20.17
Lowest Price Target
$5.00
ABCL Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to AbCellera Biologics Inc. in the past 3 months
EPS Estimates — ABCL
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.55
vs Est –$0.59
▲ 6.8% off
2025
Actual –$0.49
vs Est –$0.58
▲ 18.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ABCL
69%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.029B
vs Est $0.032B
▼ 9.5% off
2025
Actual $0.075B
vs Est $0.036B
▲ 51.7% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
